Drug intelligence / Profile preview

JNJ-64264681

Development stage: Phase 1
Lead developer: Janssen Research & Development
Modality: Small Molecules
Administration: Oral

Overview

JNJ‑64264681 is an orally bioavailable small molecule developed by Janssen Research & Development. It acts as a covalent and irreversible inhibitor of Bruton's tyrosine kinase (BTK). By binding to and inhibiting BTK activity, it blocks B-cell receptor (BCR) signaling pathways and downstream survival mechanisms in B cells. This results in the inhibition of malignant B cell growth and is being investigated for the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), and acute myeloid leukemia (AML). The drug has also shown efficacy in preclinical models of autoimmune diseases due to its role in modulating immune cell signaling[1][2][5][6][7].

Other names: 7-(4-methyl-6-(2-methylpropyl)pyridin-3-yl)-6-oxo-N-((1R,2S)-2-(prop-2-enoylamino)cyclopentyl)-2-thia-5,7,11-triazatricyclo(6.3.1.04,12)dodeca-1(11),3,8(12),9-tetraene-3-carboxamide

Targets

BTK (Bruton tyrosine kinase)

Beyond the preview

Go deeper on JNJ-64264681.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-64264681.

Explore the full profile